/
APM
$0.77-$0.00 (-0.10%)live
Held by
0
portfolios on TandT
Bookmarked by
0
users
Avg position size
—
of holders' portfolios
13F filers
0
institutions
Market cap
$6.3M
8M shares
52-week range
$0.65 – $4.47
3% from low
Exchange
NASDAQ
CS
Borrow rate
0.38%
Easy to borrow
Price (6 mo)
Loading chart…
Change$-31.18
Valuation
Financials
Loading chart…
Click rows below (any statement) to add/remove series. Selection stays as you switch tabs.
| 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $383.4K | $535.2K | $911.5K | $1.5M | $1.3M | $431.4K | $0 | $0 |
| Cost of revenue | $318.0K | $794.5K | $1.0M | $1.5M | $1.2M | $420.8K | $255.0K | $0 |
| Gross profit | $65.4K | −$259.0K | −$104.0K | $81.9K | $80.1K | $10.6K | −$255.0K | $0 |
| Gross margin | 17.1% | -48.4% | -11.4% | 5.3% | 6.2% | 2.4% | — | — |
| R&D | $3.1M | $6.9M | $11.6M | $10.9M | $9.2M | $5.2M | $1.9M | $352.9K |
| Operating income | −$10.3M | −$18.2M | −$19.9M | −$19.2M | −$17.5M | −$10.6M | −$3.8M | −$1.8M |
| EBITDA | −$10.0M | −$15.1M | $6.5M | −$25.8M | −$10.3M | −$9.5M | −$3.8M | −$1.8M |
| Net income | −$14.8M | −$18.7M | $7.1M | −$25.0M | −$9.8M | −$2.8M | −$4.3M | −$1.4M |
| Net margin | -3868.0% | -3491.8% | 775.3% | -1624.4% | -756.2% | -654.9% | — | — |
| EPS (diluted) | -5.31 | -6.40 | 2.00 | -7.15 | -2.75 | -0.62 | -0.78 | -0.19 |
Annual figures · source: Financial Modeling Prep
Analyst estimates (consensus)
| Year | Est. revenue | Est. EPS | EPS range | # Analysts |
|---|---|---|---|---|
| 2026 | $107M | $3.10 | $3.10–$3.10 | 1 |
Forward consensus · source: Financial Modeling Prep
DCF fair valuemodel estimate
Intrinsic value
$0.00
Price
$0.77
Implied downside
-100%
Peer comparison
Aptorum Group Limited Class A Ordinary Shares
Aptorum Group Ltd is a clinical-stage biopharmaceutical company. It is engaged in the discovery, development, and commercialization of therapeutic assets to treat diseases with unmet medical needs, particularly in oncology (including orphan oncology indications) and infectious diseases. Aptorum's project pipeline includes SACT-1, a repurposed drug for the treatment of neuroblastoma, and ALS-4, a small molecule for the treatment of bacterial infections caused by Staphylococcus aureus, including but not limited to Methicillin-resistant Staphylococcus aureus (MRSA). Substantially all of the company's revenues are derived from within Hong Kong.
www.aptorumgroup.com- Employees
- 2
- IPO / List date
- Dec 18, 2018
Held by traders on TradeandTell
No one on the platform currently holds APM.
Super investors & insiders
Institutions holding (13F)
No tracked institution reports a position in APM as of their last filing.
Insider activity (SEC Form 4)
Stock splits
| Execution date | Ratio |
|---|---|
| 2023-01-23 | 1-for-10reverse |
Recent trades on TradeandTell
No one on the platform has traded APM yet.
